Literature DB >> 15642428

Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.

B Gronlund1, L Lundvall, I J Christensen, J B Knudsen, C Høgdall.   

Abstract

AIM: The objective was to analyse the impact of secondary cytoreductive surgery in patients with recurrent ovarian carcinoma.
METHODS: Retrospective review of 572 consecutive patients with primary ovarian carcinoma. Thirty-eight patients with intraabdominal/pelvic recurrence consisted the study group. Clinical variables affecting tumour resectability and survival were evaluated.
RESULTS: Complete tumour resection was obtained in 42% of patients. A solitary tumour recurrence was independently associated with complete tumour resection (p=0.009). Median survival for patients with complete and incomplete tumour resection was 51.8 and 19.9 months. The parameter, residual tumour, was found independently correlated with survival after the relapse surgical procedure (p=0.02). However, including also the parameter, number of relapse tumour sites, in the multivariate analysis, the parameter, residual tumour, was no longer significantly associated with survival.
CONCLUSIONS: Complete tumour resection following secondary cytoreductive surgery is associated with improved survival in selected groups of patients with recurrent ovarian cancer. However, other clinical factors than surgical cytoreduction are of considerable significance in determining the outcome of the salvage treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642428     DOI: 10.1016/j.ejso.2004.08.016

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  10 in total

1.  Evaluation of prognostic factors for secondary cytoreductive surgery in Chinese patients with recurrent epithelial ovarian carcinoma.

Authors:  Ping Wei; Wei Zhang; Xiuxian Li; Ling Li; Yongchun Cui; Xuelian Du; Guirong Hu; Zhihu Zhang; Xiugui Sheng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Authors:  Karin K Shih; Dennis S Chi
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

3.  Survival Impact of Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer in an Asian Population.

Authors:  Rani Akhil Bhat; Yin Nin Chia; Yong Kuei Lim; Kwai Lam Yam; Cindy Lim; Melissa Teo
Journal:  Oman Med J       Date:  2015-09

Review 4.  Secondary cytoreduction for patients with recurrent ovarian cancer.

Authors:  Teresa P Díaz-Montes; Robert E Bristow
Journal:  Curr Oncol Rep       Date:  2005-11       Impact factor: 5.075

5.  Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.

Authors:  Jaeman Bae; Myong Cheol Lim; Jae-Ho Choi; Yong-Joong Song; Kyoung-Soo Lee; Sokbom Kang; Sang-Soo Seo; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

6.  Extended Pelvic Resections as Part of Secondary Cytoreduction for Relapsed Ovarian Adenocarcinoma.

Authors:  Nicolae Bacalbasa; Irina Balescu; Simona Dima; Mihaela Vilcu; Iulian Brezean
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

Review 7.  Surgical cytoreduction for recurrent epithelial ovarian cancer.

Authors:  Thuria Al Rawahi; Alberto D Lopes; Robert E Bristow; Andrew Bryant; Ahmed Elattar; Supratik Chattopadhyay; Khadra Galaal
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.

Authors:  Ting Ding; Dan Tang; Mingrong Xi
Journal:  J Ovarian Res       Date:  2021-07-13       Impact factor: 4.234

9.  Diagnosis and management of peritoneal metastases from ovarian cancer.

Authors:  Evgenia Halkia; John Spiliotis; Paul Sugarbaker
Journal:  Gastroenterol Res Pract       Date:  2012-07-19       Impact factor: 2.260

10.  Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.

Authors:  Gilles Houvenaeghel; Alexandre de Nonneville; Guillaume Blache; Max Buttarelli; Camille Jauffret; Djamel Mokart; Laura Sabiani
Journal:  J Gynecol Oncol       Date:  2022-02-04       Impact factor: 4.756

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.